CN112996538B - 免疫原性组合物 - Google Patents

免疫原性组合物 Download PDF

Info

Publication number
CN112996538B
CN112996538B CN201980072018.3A CN201980072018A CN112996538B CN 112996538 B CN112996538 B CN 112996538B CN 201980072018 A CN201980072018 A CN 201980072018A CN 112996538 B CN112996538 B CN 112996538B
Authority
CN
China
Prior art keywords
toxoid
immunogenic composition
pertussis
omvs
omv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980072018.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112996538A (zh
Inventor
M·孔托尔尼
M·皮扎
A·佐伊贝特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN112996538A publication Critical patent/CN112996538A/zh
Application granted granted Critical
Publication of CN112996538B publication Critical patent/CN112996538B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980072018.3A 2018-11-06 2019-11-04 免疫原性组合物 Active CN112996538B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18204691 2018-11-06
EP18204691.2 2018-11-06
PCT/EP2019/080120 WO2020094580A1 (en) 2018-11-06 2019-11-04 Immunogenic compositions

Publications (2)

Publication Number Publication Date
CN112996538A CN112996538A (zh) 2021-06-18
CN112996538B true CN112996538B (zh) 2025-07-08

Family

ID=64456746

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980072018.3A Active CN112996538B (zh) 2018-11-06 2019-11-04 免疫原性组合物

Country Status (14)

Country Link
US (2) US12128094B2 (enExample)
EP (1) EP3876982A1 (enExample)
JP (1) JP7469302B2 (enExample)
KR (1) KR102852282B1 (enExample)
CN (1) CN112996538B (enExample)
AR (1) AR117191A1 (enExample)
AU (1) AU2019376832B2 (enExample)
BR (1) BR112021007668A2 (enExample)
CA (1) CA3117867A1 (enExample)
EA (1) EA202190914A1 (enExample)
IL (1) IL282753B2 (enExample)
MX (1) MX2021005303A (enExample)
SG (1) SG11202103389WA (enExample)
WO (1) WO2020094580A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240082379A1 (en) 2020-12-11 2024-03-14 Glaxosmithkline Biologicals Sa Hyper-Blebbing Bacteria
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155294A1 (en) * 2013-03-27 2014-10-02 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Vaccines for the prevention of infections with bordetella

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DE60039450D1 (de) 1999-12-02 2008-08-21 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES3018133T3 (en) * 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
BR112014014950B1 (pt) * 2011-12-21 2022-03-29 Bionet-Asia, Co. Ltd Cepa de bordetella pertussis geneticamente modificada, e, métodos para produzir uma cepa de bordetella pertussis modificada e para produzir antígenos de bordetella pertussis
RU2015106791A (ru) * 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
JP2020500552A (ja) * 2016-11-23 2020-01-16 グリットストーン オンコロジー インコーポレイテッド 新生抗原のウイルスによる送達方法
ES2992907T3 (en) 2017-03-13 2024-12-19 Intravacc B V Bordetella vaccines comprising lps with reduced reactogenicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155294A1 (en) * 2013-03-27 2014-10-02 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Vaccines for the prevention of infections with bordetella

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Substitution of the Bordetella pertussis lipid A phosphate groups with glucosamine is required for robust NF-kappaB activation and release of proinflammatory cytokines in cells expressing human but not murine Toll-like receptor 4-MD-2-CD14;Nico Marr等;INFECTION AND IMMUNITY;20100228;第78卷(第5期);第2060-2069页 *

Also Published As

Publication number Publication date
AU2019376832B2 (en) 2024-01-25
IL282753A (en) 2021-06-30
CA3117867A1 (en) 2020-05-14
MX2021005303A (es) 2021-07-07
JP2022506347A (ja) 2022-01-17
US20230201325A1 (en) 2023-06-29
US20250049906A1 (en) 2025-02-13
US12128094B2 (en) 2024-10-29
KR102852282B1 (ko) 2025-09-01
IL282753B2 (en) 2025-04-01
JP7469302B2 (ja) 2024-04-16
AU2019376832A1 (en) 2021-05-13
EA202190914A1 (ru) 2021-08-03
KR20210090646A (ko) 2021-07-20
SG11202103389WA (en) 2021-05-28
EP3876982A1 (en) 2021-09-15
BR112021007668A2 (pt) 2021-07-27
AR117191A1 (es) 2021-07-21
IL282753B1 (en) 2024-12-01
CN112996538A (zh) 2021-06-18
WO2020094580A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
US20250049906A1 (en) Immunogenic compositions
JP5668049B2 (ja) 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
EA016417B1 (ru) Способ получения вакцины
JP6266631B2 (ja) 免疫原性組成物
JP2017197546A (ja) より低用量の抗原および／またはアジュバントを有する混合ワクチン
JP2008511608A (ja) 髄膜炎菌外膜ベシクルに関する改良
CN105473603B (zh) 用于登革病毒疫苗的方法与组合物
JP7650871B2 (ja) 免疫原性組成物
CA2894260A1 (en) Conjugates for protecting against diphtheria and/or tetanus
JP2015536929A (ja) スタフィロコッカス・アウレウスｓｄｒｅｃｎａｂドメイン及びワクチン接種のためのその使用
EA045827B1 (ru) Иммуногенные композиции
EA048463B1 (ru) Иммуногенные композиции

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant